Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors ...
The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback